Main > > >NEUROLOGY.

Alzheimers Disease. PROGNOSTICS.
Launch Date: 2018. 08.21.
(*) Company : Dash Genomics.
Web-Site : www.dashgenomics.com
UpDate: 2018. 08.27.




Alzheimers Disease. PROGNOSTICS.
APOE Genetic Test.
Launch Date: 2018. 08.30.
(*) Company : ADx Healthcare.
Web-Site : adxhealthcare.com
UpDate: 2018. 08.31.




Alzheimers Disease. TREAT.: Memantine.HCl Extended Release
Capsules. GENERIC.
USA Launch Date: 2018. 02.21.
(*) Company: Amneal Pharma.
UpDate: 2018. 02.22.




Alzheimers Disease. Dementia. TREAT.:
Rivastigmine Transdermal System. GENE-
RIC
USA Approval Date: 2019. 01.14.
USA Launch Date: 2019. 03.12.
(*) Company: Amneal Pharma.
UpDate: 2019. 03.13.




Alzheimers Disease. Dementia. TREAT.:
Rivastigmine Transdermal System. GENE-
RIC.
USA Launch Date: 2018. 07.09.
(*) Company: Mylan NV.
UpDate: 2018. 07.10.




Amyotrophic Lateral Sclerosis (ALS)
Treat.: Edaravone
CA Approval Date : 2018. 10.04.
JP Approval Year : 2015.
KR Approval Year : 2015.
USA Approval Date: 2017. 05.05.
USA Launch Date : 2017. 08.09.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.05.




Amyotrophic Lateral Sclerosis (ALS).
Treat.: Riluzole Oral Suspension.
USA Approval Date: 2018. 09.06.
USA Launch Date: 2018. 10.15.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.26.




AnAlgesia>Dorsal Root Ganglion (DRG) Stimulator System.
Focal Chronic Pain of the Lower Limbs due to CRPS (Complex Regional Pain Syndrome)
USA Launch Date: 2017. 10.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 04.02.




Assessment. Bioimpedance Asymmetry Detection.
Fluid Volume Differences between the Cerebral Hemispheres in Patients undergoing Neurologic Assessment.
Portable non-invasive device.
USA Clearance Date: 2018. 01.04.
(*) Company; Patent & TradeMarks Available on Request.
UpDate: 2018. 01.05.




Balance. Assessment Tool.
USA FDA 510(k) Clearance: 2018. 04.17.
(*) Company; TradeMark & Web-Site
Available on Request.
UpDate: 2018. 04.18.




CentroNuclear Myopathy. Treat.:
Dynamin 2 Inhibitor (AntiSense Oligo
nucleotide).
Status: Dev.
(*) Company; Patent APP.; Product Name
& Web-Site Available on Request.
UpDate: 2018. 08.15.




Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
TREAT.: Immune Globulin Subcutaneous [Human] 10% Liquid.
JP Approval Date: 2019. 03.26.
USA Approval Date: 2017. 09.14.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.27.




Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
TREAT.: Immune Globulin Subcutaneous [Human] 20% Liquid.
EU Approval Date : 2018. 03.15.
JP Approval Date : 2019. 03.26.
USA Approval Date: 2018. 03.16.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.27.




Dravet Syndrome. Treat.: Stiripentol+
Clobazam.
[Also Called: Severe Myoclonic Epilepsy in Infancy (SMEI)].
Stiripentol Structure:
4-dimethyl-1-[(3,4-methylenedioxy)-phenyl]-1-penten-3-ol
CA Approval Date : 2012. 12.21.
EU Approval Date : 2014. 01.08.
JP Approval Date : 2012. 09.28.
USA Approval Date: 2018. 08.23.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 08.26.




Epilepsy. Complex Partial Seizures (CPS). TREAT.: Vigabatrin Tablets. GENERIC.
USA Approval Date: 2019. 01.16.
USA Launch Date: 2019. 02.06.
(*) Company: Teva Pharma USA.
UpDate: 2019. 02.07.




Epilepsy. Smart Watch.
Uses AI (advanced machine learning) to monitor for the most dangerous kinds of seizures, known as "grand mal" or "generalized tonic-clonic" seizures, and send an alert to summon caregivers s help.
USA Clearance Date: 2018. 02.05.
(*) Company : Empatica SRL. www.empatica.com/en-eu
TradeMark: Embrace.
Web-Site : www.empatica.com/en-eu/embrace/
UpDate: 2018. 02.07.




Epilepsy. TREAT.: Cannabidiol Oral So-
lution.
Dravet Syndrome.
Lennox-Gastaut Syndrome.
USA Approval Date: 2018. 06.25.
USA Launch Date : 2018. 11.01.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2018. 11.02.




Epilepsy. TREAT.: Levetiracetam Tablets
for Oral Suspension.
3D Printed.
USA Approval Date: 2015. 08.03.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.08.




Essential Tremor. TREAT.: MR-Guided Focused UltraSound.
Approved in CA; EU & IL.
TW Approval Date: 2017. 11.29.
USA Approval Date: 2017. 05.09.
(*) Company Available on Request.
UpDate: 2017. 11.30.




IMAGING: MagnetoEncephaloGraphy (MEG) (JP) Measurement System.
Noninvasive Way to Detect Faint Signals within the Brain. It provides Deeper Measurement (Hippocampus and Hypothalamus), Clearer Signal using Coaxial Gradiometer Sensors and Greater Patient Comfort for Better Data Acquisition.
USA FDA 510(k) Clearance Date: 2017. 11.30.
(*) Company Available on Request.
UpDate: 2017. 12.01.




IMAGING: MagnetoEncephaloGraphy (MEG) (SE) Measurement System.
Noninvasive Way to Detect Faint Signals within the Brain. It provides Deeper Measurement (Hippocampus and Hypothalamus), Clearer Signal using Coaxial Gradiometer Sensors and Greater Patient Comfort for Better Data Acquisition.
Introduction Date: 2017. 12.01.
(*) Company; PR Web-Site & TradeMark
Available on Request.
UpDate: 2017. 12.02.




Huntingtons Disease. TREAT.: Tetrabenazine Tablets. GENERIC.
USA Launch Date: 2018. 02.02.
(*) Company: — Dr. Reddy s Laboratories Ltd.
UpDate: 2018. 02.03.




Lambert-Eaton Myasthenic Syndrome (LEMS)
Treat.: Amifampridine Tablets.
CA Approval Date : 2020. 08.06.
EU Approval Date : 2009. 12.22.
USA Approval Date: 2018. 11.29.
(*) Company; Patent; TradeMark & Web-
Site Available on Request
UpDate: 2020. 10.07.




Motion Sickness. Virtual Reality (VR) Motion Sickness.
Navigation Technology. (Drone & Theater).
Launch Date: 2018. 02.06.
(*) Company; Patents; TradeMark & Web-Sites Available on
Request.
UpDate: 2018. 02.07.




Multiple Sclerosis TREAT.: Cladribine Tablets.
RRMS: Relapsing-Remitting MS.
SPMS: Secondary Progressive MS.
CA Approval Date : 2017. 12.04.
EU Approval Date : 2017. 08.25.
USA Approval Date: 2019. 03.29.
(*) Company; TradeMark; Patents & Web-
Site Available on Request.
UpDate: 2019. 03.31.




Multiple Sclerosis. TREAT.: OcrelizuMAb.
(Primary Progressive MS) &
("Relapsing"-Remitting).
EU Approval Date: 2018. 01.12.
USA Approval Date: 2017. 03.28.
(*) Company; Patent; TradeMark & Web-Site Available on
Request.
UpDate: 2018. 01.13.




Myasthenia Gravis. TREAT.: EculizuMAb.
(Anti-AChR) AB-+)
EU Approval Date: 2017. 08.21.
JP Approval Date: 2017. 12.26.
USA Approval Date: 2017. 10.23.
(*) Company & TradeMark Available on Request.
UpDate: 2017. 12.28.




Neuralgia (Neuropathic Pain) that follows healing of Shingles (a painful rash that comes after a Herpes zoster infection). Treat.: Gabapentin Tablets.
USA Approval Date: 2011. 01.28.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 04.23.




Pain. Treat.: RF Ablation Generator.
USA Launch Date: 2020. 11.10.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 03.01.




Parkinsons Disease. DysKinesia. TREAT.: Amantadine.HCl ER
Capsules.
L-DOPA Induced.
USA Approval Date: 2017. 08.24.
USA Launch Date: 2018. 01.08.
(*) Company; Patents; TradeMark & Web-Site Available on
Request.
UpDate: 2018. 01.10.




Parkinsons Disease. Prognostics.
USA Approval Date: 2017. 04.06.
(*) Company; Patent & PR Web-Site
Available on Request.
UpDate: 2020. 01.20.




Parkinsons Disease. Psychosis. TREAT.:
Pimavanserin. (U)
5-HT2A Receptor Inhibitor.
- 10 Mg Tablet.
(patients who are concomitantly
receiving strong cytochrome 3A4
inhibitors which can inhibit the
metabolism of Pimavanserin)
USA Approval Date: 2018. 06.29.
- 17 mg Tablet (2 Times a Day)
USA Approval Date: 2016. 05.31.
- 34 mg Capsule (1 Time a Day)
USA Approval Date: 2018. 06.29.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 07.16.




Parkinsons Disease. Symptoms. TREAT.: Deep Brain Stimulation (DBS) System.
AU>Approval
EU>Launch
IL>Approval
USA>Approval Date: 2017. 12.11.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2017. 12.13.




Parkinsons Disease. TREAT.: Deep Brain
Stimulation (DBS) System.
EU Approval Date : 2015. 09.
USA Approval Date: 2016. 10.06.
USA Approval Date: 2020. 01.24.>
>to include targeting of an area of the
brain called the internal globus
pallidus (GPi).
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 02.11.




Parkinsons Disease. TREAT.: Levodopa
Inhalation Powder.
OFF episodes in patients with Parkinson s disease treated with carbidopa/levo-dopa.
USA Approval Date: 2018. 12.21.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.26.




Parkinsons Disease. TREAT.: SafinAmide
Tablets.
AU Approval Date : 2018. 11.30.
CA Approval Date : 2019. 01.15.
CH Approval Date : 2015. 11.
EU Approval Date : 2015. 02.
USA Approval Date: 2017. 03.21.
USA Launch Date : 2017. 07.11.
(*) Companies; Patents; TradeMarks &
Web-Site Available on Request.
UpDate: 2019. 01.16.




Sialorrhea. TREAT.: Inco Botulinum Toxin
A. (D)
Also Called: HyperSalivation; Ptyalism.
USA Approval Date: 2018. 07.03.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 07.16.




Spasticity. Limb Spasticity. TREAT.: AboBotulinumToxinA.
(Botulinum Toxin A).
Lower Limb>USA Adults Approval Date: 2017. 06.16.
Lower Limb>USA Pediatrics Approval Date: 2016. 08.01.
Upper Limb>CA Adults Approval Date: 2017. 03.14.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2017. 12.19.




Spasticity. Limb Spasticity. TREAT.: OnaBotulinumToxinA.
(Botulinum Toxin A).
Upper Limb>USA Approval Date: 2010. 03.
Lower Limb>USA Approval Date: 2016. 01.22.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2017. 12.19.




Spasticity. TREAT.: Tizanidine.HCl Capsules.
USA Approval Date: 2002. 08.29.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2017. 12.19.




Spinal Cord Injury (SCI). TREAT.: Robotic Device.
Improve a Patient s Ability to Walk.
USA Launch Date: 2018. 03.02.
(*) Companies; Patent; TradeMark & Web-Site Available
on Request
UpDate: 2018. 03.03.




Stroke. Acute Ischemic Stroke. TREAT.: Aspiration System.
The Aspiration System is designed to retrieve thrombus (or blood clot) through the Arc(TM) Catheter and restore blood flow in patients experiencing blockage of an artery in the brain, known as an ischemic stroke. The procedure involves inserting a catheter through an incision in the leg and up to the blocked artery allowing the physician to remove the blood clot.
The Aspiration System is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral - M1 and M2 segments, basilar and vertebral arteries) within eight (8) hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.
USA Clearance Date: 2018. 01.17.
(*) Company : Medtronic.
TradeMark: Riptide.
UpDate: 2018. 01.18.




Stroke. Acute Ischemic Stroke. TREAT.: Thrombectomy Device.
(I)
EU Approval Date: ?
(*) Company; Patents; TradeMarks & Web-Site Available on
Request.
UpDate: 2018. 02.17.




Stroke. Acute Ischemic Stroke. TREAT.: Thrombectomy Device.
(U)
Patients experiencing acute ischemic stroke up to 24 hours from symptom onset – increasing the treatment window by 18 hours.
USA FDA Clearing Date: 2018. 02.15.
(*) Company : Stryker. www.stryker.com/us/en
TradeMark: Trevo® Retriever
UpDate: 2018. 02.17.




Stroke. Bioimpedance Asymmetry Detection. IntraCranial Fluids Monitor.
EU Approval Date: 2017. 11.29.
(*) Company; Patent & TradeMarks Available on Request.
UpDate: 2017. 11.30.




Stroke. Prevention. Canagliflozin Ta-
blets. Diabetes Type II Patients.
USA Approval Date: 2018. 10.30.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.31.




Stroke. Prevention. Semaglutide Inj.
Diabetes Type II Patients.
USA Approval Date: 2020. 01.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.18.




Stroke. SubArachnoid Haemorrhage (SAH).
Treat.: Sulforaphane+Cyclodextrin Com-
plex.
IUPAC Name: 1-Isothiocyanato-4-
methylsulfinylbutane
Status: Phase II
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 08.19.




Stroke. Treat.: Cooling.
USA Approval Date: 2018. 05.29.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.07.




Tourette Syndrome. Treat.: Human D1 Receptor AntAgonist. Ecopipam.
Status: Phase IIB
(*) Company; Patent & Web-Site Avai-
lable on Request.
UpDate: 2018. 08.15.




TransThyRetin Amyloid NeuroPathy. Treat.
: Patisiran Lipid Complex Injection.
Hereditary.
RNA Interference.
BR Approval Date : 2020. 02.26.
DE Launch Date : 2018. 10.02.
EU Approval Date : 2018. 08.30.
JP Approval Date : 2019. 06.18.
USA Approval Date: 2018. 08.10.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 04.07.




TransThyRetin Amyloid NeuroPathy. Treat.
: Tafamidis Capsules.
Also Approved in: AR, BR, IL, KR, MX &
RU
EU Approval Year: 2011.
JP Approval Year: 2013.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 02.20.


>NEUROLOGY.'s products
This section has no products